Clinical Trial Update: Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating durvalumab plus olaparib given before surgery in resectable bladder cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Olaparib (Olaparib)

Snippet

Sponsor: Spanish Oncology Genito-Urinary Group | Conditions: Bladder Cancer | Phase 2 | Status: COMPLETED